Sheet

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use as many sheets as necessary)

of 1

			U.S. PATEN	T DOCUMENTS		
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
initials*	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Citied Document	Relevant Passages or Relevant Figures Appear	
	US7	4,493,796	01-15-1985	Rinehart, Jr.		
	US8	4,782,135	11-01-1988	Rinehart, Jr.		
	US9	5,137,870	08-11-1992	Rinehart		
	US10	5,504,189	04-02-1996	Emling et al.		
	US11	7,064,105 B2	06-20-2006	Joullié et al.		
	US12	7,122,519 B2	10-17-2006	Joullié et al.		
	US13	2003/0104991 A1	06-05-2003	Joullie et al.		
	US14	2007/0129289 A1	06-07-2007	Joullie et al.		
		AII P	FEERENCES	I CONSIDERED EXCEPT	WHERE LINED THROUGH. 7M	

		F	OREIGN PA	TENT DOCUMENTS		
Fuendana		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Examiner initials*	Cite No.1	Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Citied Document	Where Relevant Passages or Relevant Figures Appear	Т6
	FP2	ES 2 102 322 A1	07-16-1997	Pharma Mar, S.A.		
	FP3	WO 98/17302 A1	04-30-1998	The Board of Trustees of the University of Illinois		
	FP4	WO 98/17302 A1 (Corrected Version)	04-30-1998	The Board of Trustees of the University of Illinois		
	FP5	WO 98/17275 A1	04-30-1998	The Board of Trustees of the University of Illinois		
	FP6	WO 02/02596 A2	01-10-2002	Pharma Mar, S.A.		

1125118\_1.DOC

Examiner Signature /Marcela Cordero Garcia/ Date Considered 11/15/2010

"EXAMINET, Initial I releases considered, whether or not otation is in conformance with MPEP 690. Draw line through claims in inct in conformance and not considered include copy of this form with next communication to appoint "Applicants' unique catation designation number (oplicants) ese (MISCOdes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (MIPPO Standard ST.3). \*For Japanese patent of coursets, the indication of the year of the regind of the Emproyer must precede the serial number of the patent document that the control of coursets the indication of the year of the regind of the Emproyer must precede the serial number of the patent document that of document to the special coursets of the special courset of the patent document of the patent document to the pat

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to proceed) an application. Confidentially is gonemed by 59 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to be Dours to complete including gathering, peparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the mount of time upon required to complete this form andion's suggestions for evolucing this burders, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA.22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450.

CORDERO GARCIA, MARCELA

1694.0610001/JMC/THN

Receipt date: 09/20/2010 Complete if Known Substitute for form 1449/PTO 10/550.196 Application Number FIRST SUPPLEMENTAL January 12, 2007 Filing Date Madeleine M. Joullie INFORMATION DISCLOSURE First Named Inventor Art Unit STATEMENT BY APPLICANT

> Examiner Name Attorney Docket Number

(Use as many sheets as necessary)

of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials®	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, etty and/or country where published	T
	NPL48	Abdel-Magid, A.F., et al., "Reductive Amination of Aldehydes and Ketones by Using Sodium Tricetoxyborohydride," <i>Tetrahedron Lett.</i> 31:5595-5598, Pergamon Press plc, UK (1990)	
	NPI.49	Abdel-Magid, A.F. & Maryanoff, C.A, "Reductive Amination of Aldehydes and Ketones with Weakly Basic Anilines Using Sodium Triacetoxyborohydride," <i>Synlett.</i> 537-539, Germany (1990)	
	NPL50	Ahuja, D., et al., "Inhibition of Protein Synthesis by Didemnin B: How EF-1a Mediates Inhibition of Translocation," <i>Biochemistry</i> 39:4339-4346, American Chemical Society, United States (2000)	
	NPL51	Ahuja, D., et al., "Inhibition of Protein Synthesis by Didemnins: Cell Potency and SAR," J. Med. Chem. 43:4212-4218, American Chemical Society, United States (2000)	
	NPI.52	Campbell, MJ., et al., "Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl.)all-trans retinamide," Brit. J. of Cancer 77:739-744, Cancer Research Campaign, UK (1998)	
	NPL53	Crews, C.M., et al., "Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis," Proc. Natl. Acad. Sci. USA 93:4316-4319, Natl. Acad. Sci., United States (1996)	
	NPL54	Ding, X., et al., "Structure-Activity Relationships of Side-Chain Modified Didemnins," Bioorg, Med. Chem. Lett. 11:231-234, Elsevier Science Ltd., United States (2001)	
	NP1.55	Ewing, W.R., et al., "SYNTHETIC STUDIES OF DIDEMNINS. I. REVISION OF THE STEREOCHEMISTRY OF THE HYDROXYISOVALERYLPROPIONYL (HIP) UNIT.," Tetrahedron 42:3863-5868, Pergamon Journals Ltd., UK (1986)	
	NPL56	Ewing, W.R., et al., "SYNTHETIC STUDIES OF DIDEMNINS. IV. SYNTHESIS OF THE MACROCYCLE," Tetrahedron Lett. 30:3757-3760, Maxwell Pergamon Macmillan ple, UK (1989)	
	NPL57	Harris, B.D., et al., "SYNTHETIC STUDIES OF DIDEMNINS. II. APPROACHES TO STATINE DIASTEREOMERS," Tetrahedron Lett. 28:2837-2840, Pergamon Journals Ltd., UK (1987)	

## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Signature	Date Considered
	WARTER COO. Down by the state of and an engineering and

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in c not considered. Include copy of this form with next communication to applicant.

Applicant's unique ortation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

				Equivalent of Form PTO/SB/088 (7-09	
Substitute for	form 1449/PTO		Complete if Known		
		Application Number	10/550,196		
FIRST S	SUPPLEMEN	TAL	Filing Date	January 12, 2007	
INFORMATION DISCLOSURE			First Named Inventor	Madeleine M. Joullie	
STATE	MENT BY AP	PLICANT	Art Unit	1654	
OTATE	(Use as many sheets		Examiner Name	CORDERO GARCIA, MARCELA M.	
Sheet	2 of	4	Attorney Docket Number	1694.0610001/JMC/THN	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL58	Harris, B.D., et al., "SYNTHETIC STUDIES OF DIDEMNINS. III: SYNTHESES OF STATINE AND ISOSTATINE STEREOISOMERS," Tetrahedron 44:3489-3500, Pergamon Press ple, UK (1988)	
	NPI.59	Jou, G., et al., "Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution," J. Org. Chem. 62:354-366, American Chemical Society, United States (1997)	
	NPL60	Joullié, M.M., et al., "Total Synthesis of (-)-tamandarin B," Tetrahedron Lett. 41:9373-9376, Elsevier Science Ltd., UK (2000)	
	NPL61	Joullié, M.M., et al., "Chemical Defense in Ascidians of the Didemnidae Family," Bioconjugate Chem. 14:30-37, American Chemical Society, United States (2003)	
,	NPL62	Li, WR. & Joullié, M.M., "The Didemnins: Biological Properties, Chemistry and Total Synthesis," Studies in Natural Products Chemistry, 10:241-302, Elsevier Science Publishers B.V., The Netherlands (1992)	
	NPL63	Mayer, S.C., et al., "Synthesis of New Didemnin B Analogs for Investigations of Structure/Biological Activity Relationships," J. Org. Chem., 59:5192-5205, American Chemical Society, United States (1994)	
	NPL64	Mayer, S.C., et al., "Synthetic Routes to a Constrained Ring Analog of Didemnin B," J. Org. Chem. 61:1655-1664, American Chemical Society, United States (1996)	
	NPL65	Mayer, S.C., et al., "Synthetic Studies of a Constrained Ring Didenmin Analog." Tetrahedron: Asymmetry 5:519-522, Elsevier Science Ltd., UK (1994)	
	NPL66	Mayer, S.C., et al., "The Cyclic Depsipeptide Backbone of the Didemnins," Acta. Cryst. C51:1609-1614, International Union of Crystallography, UK (1995)	
	NPL67	Pfizenmayer, A.J., et al., "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF [N-McLeu <sup>5</sup> ) DIDEMNIN B," Biog. Med. Chem. Lett. 6:2713-2716, Elsevier Science Ltd., UK (1996)	

## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner	Date	
Signature	Considered	

\*EXAMINER- Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not clation is in conformance with MFLP\* USU. Livis whe through clation is not considered include copy of this form with next communication to applicant considered include copy of this form with next communication to applicant a unique clation designation number (optional). \*Applicant to place a check mark here if English Impugned Frantisation is rated by 37 CFR 19 This collection of information is required to obtain or retain a benefit by the public which a to file (and by the USFTO to process) an application. Contidentiality is governed by 38 U.S.C. 122 and 37 CFR 19 The This collection of its observed to take 2 hours to complete including statement, preparing, and substituting the completed application from the USFTO (time will vary deposited to state) to complete including statement, preparing, and substituting the complete displication form and/or suggister, preparing and sold officers. On the complete its contraction and continued in the Complete ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 09/20/2010

					Equivalent of Form PTO/SB/085 (7-09	
Substitute for form 1449/PTO				Complete if Kuowu		
				Application Number	10/550,196	
FIRST S	SUPPLE	MEN.	TAL	Filing Date	January 12, 2007	
INFORMATION DISCLOSURE				First Named Inventor	Madeleine M. Joullie	
STATE	MENTB	YAP	PLICANT	Art Unit	1654	
(Use as many sheets as necessary)				Examiner Name	CORDERO GARCIA, MARCELA M.	
Shect	3	of	4	Attorney Docket Number	1694.0610001/JMC/FHN	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL68	Portonovo, P., et al., "First Total Synthesis of a Fluorescent Didemnin," Tetrahedron 56:3687-3690, Elsevier Seience Ltd., UK (2000)	
	NPL69	Ramanjulu, J.M., et al., "A Facile Synthesis of Benzyl 2-Amino-3-Azido-4-O-p-Methoxybenzyl-6-O-Benzyl-2,3-Dideoxy-a-D-Glucopyranoside: A Key Intermediate in the Formation of a Didemnia B Analog." J. Carbohydrate Chemistry 15:371-381, Marcel Dekker, Inc., United States (1996)	
	NP1.70	Ramanjulu, J.M., et al., "Analogs of the β-Turn of the Cyclodepsipeptide Didemnin B," Tetrahedron Letters 37:311-314, Elsevier Seience Ltd., UK (1996)	
	NPL71	Ramanjulu, J.M., et al., "Syntheses of Acyclic Analogs of Didemnin B," Synthetic Communications 27:3259-3272, Marcel Dekker, Inc., United States (1997)	
	NPI.72	Ramanjulu, J.M., et al., "Synthesis of a Reduced Ring Analog of Didemnin B," J. Org. Chem. 62:4961-4969, American Chemical Society, United States (1997)	
	NPL73	Ramanjulu, J.M., et al., "Synthetic Studies of a Didemnin B Analog Based on a 2,3- Diamino Sugar Scaffolding," <i>J. Chin. Chem. Soc.</i> 48:1-4, The Chemical Society, Taiwan (2001)	
	NPL74	Schumacher, K.K., et al., "Synthetic studies toward astins A, B and C. Efficient syntheses of Cis-3,4-dihlydroxyptolines and (-) (33,4R)-dichloroproline esters," Tetrathedrox: Asymmetry 9,47-53, Elsever Seience Ltd., UK (198)	
	NPL75	Tarver Jr., J.E., et al., "Total Syntheses of Conformationally Constrained Didemnin B Analogues. Replacements of N. O-Dimethyltyrosine with L-1,2,3.4 Tetrahydroisoquinoline and L-1,2,3.4-Tetrahydro-7-methoxyisoquinoline," J. Org. Chem. 66:7375-7587, American Chemical Society, United States (2001)	
	NPL76	Vera, M.D., et al., "[Lys³] Didemnins as Potential Affinity Ligands," Biorg. Med. Chem. Lett. 11:13-16, Elsevier Science Ltd., UK (2001)	
	NPL77	Vera, M.D. & Joullié, M.M., "Natural Products as Probes of Cell Biology: 20 Years of Didemnin Research," <i>Medicinal Research Reviews</i> 22:102-145, John Wiley & Sons. Inc., United States (2002)	

## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M.C.G./

Examiner		Date	
Signature		Considered	
 	The state of the s	in MDED 600 Deput E	on through citation if not in conformance and

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a brendf by the public which is to file (and by the USPTO to process) an application. Confidentiably a governor by CZP 22 and 37 CFR 1.14. The collection is estimated to lake 2 hours to complete. USPTO to process an explication form to the USPTO. Time will vary depending upon the individual case. Any comments are the amount of time year acquired to complete this form and/or suggestions for reducing this butteria, broad to serve you acquired to complete the form and/or suggestions for reducing this butteria, broad to serve you acquired to complete the form and/or suggestions for reducing this butteria, broad to serve you are the server of the s

1694 0610001/JMC/THN

Receipt date: 09/20/2010 Substitute for form 1449/PTO Complete if Known 10/550.196 Application Number FIRST SUPPLEMENTAL January 12, 2007 Filing Date INFORMATION DISCLOSURE First Named Inventor Madeleine M. Joullie Art Unit 1654 STATEMENT BY APPLICANT CORDERO GARCIA, MARCELA (Use as many sheets as necessary)

4 of 4

Examiner Name

Attorney Docket Number

SHOOL	7	of 4 Automost Top to to to the Title
		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, ctc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
2 10 (11	NPL78	Vera, M.D., et al., "Synthesis and Biological Evaluation of Didemnin Photoaffinity Analogues," Biorg. Med. Chem. Lett. 11:1871-1874, Elsevier Science Ltd., UK (2001)
* 170 Y 00 TO	NP1.79	Vervoort, H. & Fenical, W., "Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae," <i>J. Org. Chem.</i> 65:782-792, American Chemical Society, United States (2000)
Pro subset Fred 1 1 1	NPL80	Wipf, P., "Synthetic Studies of Biologically Active Marine Cyclopeptides," Chem. Rev. 95:2115-2134, American Chemical Society, United States (1995)
	NPL81	Xiao, D., et al., "Total Synthesis of a Conformationally Constrained Didenmin B," J. Org. Chem. 66:2734-2742, American Chemical Society, United States (2001)
	NPL82	STNEasy/CAplus English language Abstract of Spanish Patent Publication No. ES 2 102 322 A1 (1997), document FP1, Accession No. 1998:169709

1125067 LDOC

Sheet

## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /M.M.C.G./

Examiner Signature	/Marcela Cordero Garcia/	Date Considered	11/15/2010	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case Any mments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandra, V.A 22313-1450. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandra, V.A 22313-1450.